drugset / Trial / NCT05810961
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).
Timeline
- Start
- 2023-02-20
- Primary completion
- 2024-08-05
- Completion
- 2024-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgartigimod Alfa | Protein / enzyme biologic | — | Intravenous |